GSK Gains Lovaza By Acquiring Reliant For $1.65 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Addition of the triglyceride treatment will complement GSK’s Coreg CR physician base, company tells “The Pink Sheet” DAILY.
You may also be interested in...
Generic Coreg To Launch Immediately Following FDA Approval
Several generic drug makers received ANDA approval for generic versions of GlaxoSmithKline’s blockbuster heart failure medication.
Reliant Submits Response To FDA For Expanded Omacor Indication
Company seeks an indication for the omega-3 ester to treat high triglycerides as an adjunct to diet and statin therapy.
With One Launch Under Way, SpringWorks Ramps Up For A Second
The company initiated a rolling submission with the US FDA for mirdametinib, a MEK inhibitor that is poised to be its second commercial product for a rare disease.